Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast: Regional Insights & Projections
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast: Regional Insights & Projections
The global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market is witnessing significant growth, driven by the rising prevalence of chronic pain conditions and the increasing preference for NSAIDs over opioids. This report provides an in-depth analysis of the market's current status, key players, recent developments, and future prospects.
The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market is witnessing consistent growth globally due to the increasing prevalence of chronic pain, inflammation, arthritis, and musculoskeletal disorders. NSAIDs are widely used for their analgesic, antipyretic, and anti-inflammatory effects, making them a cornerstone in pain management therapy.These medications are available in prescription and over-the-counter (OTC) forms, including tablets, capsules, topical creams, and injectables. Common examples include ibuprofen, naproxen, diclofenac, and aspirin.
According to Fortune Business Insights, the non-steroidal anti-inflammatory drugs (NSAIDs) market was valued at USD 15.58 billion in 2019 and is projected to reach USD 32.33 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period. North America dominated the market in 2019, holding a share of 44.03%.
GlaxoSmithKline plc
Pfizer Inc.
Johnson & Johnson Services, Inc.
Bayer AG
AstraZeneca
Boehringer Ingelheim International GmbH
Zyla Life Sciences
Horizon Therapeutics plc
Others
Development of Selective COX-2 Inhibitors: Research is focused on developing NSAIDs that minimize gastrointestinal side effects.Â
Topical NSAIDs: Increasing adoption due to localized treatment and reduced systemic exposure.
Combination Therapies: Companies are developing combination drugs to enhance efficacy and patient compliance.
In May 2019, Perrigo Company plc announced the FDA approval for an Abbreviated New Drug Application (ANDA) referencing Voltaren Gel. This approval is expected to enhance the availability of effective NSAID treatments for patients.
Increasing prevalence of chronic pain conditions such as arthritis and migraines.
Growing preference for NSAIDs over opioids due to lower risk of addiction.
Advancements in drug formulations enhancing efficacy and safety.
Potential adverse effects associated with long-term NSAID use, including gastrointestinal and cardiovascular risks.
Regulatory scrutiny and the need for stringent pharmacovigilance.
Patent expirations leading to increased generic competition.
This report covers comprehensive insights into the NSAIDs market, including market size, growth trends, competitive landscape, and segmental analysis. It provides a detailed examination of the factors influencing market dynamics and offers strategic recommendations for stakeholders.
The NSAIDs market is characterized by the presence of several key players focusing on strategic collaborations, product launches, and research and development activities to strengthen their market position. Companies are investing in developing safer and more effective NSAID formulations to meet the growing demand.
Disease Indication: The arthritis segment is expected to lead the market during the forecast period, attributed to the high prevalence of arthritis and osteoarthritis globally. NSAIDs are commonly prescribed for managing pain and inflammation associated with these conditions.
Route of Administration: Oral administration remains the most common route for NSAIDs, followed by topical and parenteral methods. The choice of administration depends on the specific condition being treated and patient preferences.
Distribution Channel: Retail pharmacies hold the largest share in the distribution of NSAIDs, with hospital pharmacies and online pharmacies also contributing significantly to the market.
Explore the full research report with detailed insights and TOC:http://fortunebusinessinsights.com/non-steroidal-anti-inflammatory-drugs-nsaids-market-102823Â
North America: North America is expected to hold the highest market share, driven by the high prevalence of chronic pain conditions and the presence of major pharmaceutical companies.
Europe: Europe follows closely, with increasing awareness about pain management and a growing aging population contributing to market growth.
Asia-Pacific: The Asia-Pacific region is anticipated to witness significant growth due to rising healthcare expenditure, increasing awareness about NSAIDs, and a large patient population.
The NSAIDs market is poised for continued growth, with ongoing research focusing on developing selective COX-2 inhibitors to minimize adverse effects. Additionally, the integration of digital health technologies and personalized medicine approaches is expected to revolutionize patient access and treatment outcomes.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com